APOE and Alzheimer disease: These findings suggest that dysregulated lipid composition in APOE4/4 BDEVs, especially enrichment of FFA 18:2, may drive tau pathology, potentially exacerbating neuroinflammation and disease progression in APOE4 AD cases.